| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 2 |
Editorial Board
|
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 3 |
European Society for Medical Oncology (ESMO)
|
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 4 |
28MO Adapting the Time-to-Event Continual Reassessment Method (TiTE-CRM) to include consolidation immunotherapy in a phase I drug-radiotherapy platform trial
|
Kendall, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 5 |
79MO Developing international consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding clinical trials: The DEFINE (DosE FIndiNg Extensions) study
|
Solovyeva, O.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 6 |
70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial
|
Botticelli, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 7 |
80MO Optimising participant flow diagrams for phase I clinical trials
|
Alger, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 8 |
Notice and Disclaimer
|
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 9 |
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target
|
Yap, T.A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 10 |
109O Phase I study of MEDI9253, a recombinant Newcastle Disease Virus encoding interleukin-12, in combination with durvalumab in participants with select advanced/metastatic solid tumors
|
Postel-Vinay, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 11 |
46O Preliminary results from a phase IA trial of selective FGFR1-3 inhibitor CPL304110 in patients with FGFR-deregulated advanced solid malignancies
|
Lugowska, I.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 12 |
1O Safety, pharmacokinetics, efficacy, and biomarker results of SRK-181 (a latent TGFβ1 inhibitor) from a phase I trial (DRAGON trial)
|
Yap, T.A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 13 |
9P An in vivo model for therapeutic antibody efficacy evaluation: The chicken embryo’s CAM-based assay
|
Wang, Y.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 14 |
95P Anticancer activity of Inula recemosa root extract in human liver cancer cell line by attenuation of OCT4/Sox2 axis
|
Sarkar, T.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 15 |
62P Anti-malarial drug quinacrine: A potential molecule for repurposing in targeting human non-small cell lung cancer cells (NSCLC)
|
Sarkar, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 16 |
52P Antitumor efficacy of polypyrrole-polyethyleneimine nanocomplex to target B-cell lymphoma
|
Nguyen, T.T.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 17 |
29P A phase I, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced solid tumors
|
Fan, Y.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 18 |
42P Apigenin: An immunomodulatory nutraceutical overriding PD-L1 inhibitors by halting AKT/mTOR pathway in triple-negative breast cancer (TNBC)
|
Samir, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 19 |
31P Association of PD-L1 expression and autophagy in patients with ovarian cancer
|
Jovanovic, L.Z.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 20 |
73P Automated detection of typical and atypical mitotic figures for improving survival prediction in breast cancer
|
Ben Hadj, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 21 |
97P Bcl-xL prevents the arginine starvation induced by PEGylated arginine deiminase (ADI-PEG20) from inducing apoptosis
|
Van Tine, B.A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 22 |
41P BRCA2 pathogenic variant (PV): A novel agnostic biomarker for immune checkpoint blockers (ICB)?
|
Alonso de Castro, B.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 23 |
98P Cationic dendrimers as prospective vehicles of therapeutic nucleic acids into tumor cells: Approaches, advantages and challenges
|
Knauer, N.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 24 |
107P Censoring imbalance in ACIS trial for prostate cancer
|
Zimhony-Nissim, N.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 25 |
53P Characterization of the non-ATP competitive PI3Kdelta inhibitor IOA-244 in lymphoma models: From single agent to combination screen and clinical investigation
|
Bertoni, F.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 26 |
104P Choline transporter-like protein 1 is a novel molecular target for the treatment of hepatocellular carcinoma
|
Inazu, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 27 |
93P Circulating cell-free DNA fragmentation profiles during systemic therapy of advanced-stage non-small cell lung cancer patients
|
Milovanovic, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 28 |
32P Clinical efficacy and safety of an immune checkpoint inhibitor in combination with regorafenib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma
|
Li, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 29 |
87P Clinical features and genetic profile of MDM2-altered solid tumors
|
Tejerina-Peces, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 30 |
102P Co-expression analysis of genes encoding proteasome subunits and XPO1-related proteins in the Cancer Genome Atlas (TCGA) and the Gene Tissue Expression (GTEx) databases as a tool to devise new treatment strategies
|
Spataro, V.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 31 |
92P Comprehensive multigene profiling impact on clinical decisions in patients with advanced cancers: A multicenter, retrospective analysis
|
Kuznetsova, O.A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 32 |
3P Correlation between antibody-drug conjugate (ADC) targetable antigen expression and occurrence of interstitial lung disease (ILD)
|
Peters, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 33 |
12P CRISPR/Cas9-induced knock-out of DGKαζ in TAG-72 CAR-T cells improves function and persistence in ovarian cancer
|
Evtimov, V.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 34 |
21P Cross-resistance between platinum-based chemotherapy (PlCh) and PARP inhibitors (PARPi) in castration-resistant prostate cancer (CRPC)
|
Slootbeek, P.H.J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 35 |
82P Cyclic fasting-mimicking diet as a strategy to improve the efficacy of standard antitumor therapies in cancer patients
|
De Braud, F.G.M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 36 |
57P Deciphering the role of E2F transcription factor-1 in glutamine metabolism
|
Huber, K.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 37 |
30P Deep learning approach for discovering new predictive histological features of immunotherapy response
|
Ben Hadj, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 38 |
40P Development of radiolabelled plerixafor as a theranostic molecule for targeting CXCR4 receptor expressing cancers: A translational study
|
Lakhanpal, T.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 39 |
45P Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer
|
Levin, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 40 |
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?
|
Yap, C.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 41 |
90P Effect of age on safety and efficacy of novel cancer drugs investigated in early phase clinical trials
|
Uliano, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 42 |
48P Efficacy analysis and mechanism exploration of furmonertinib for advanced NSCLC with EGFR exon 20 insertion mutation
|
Zhang, X.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 43 |
10P Efficacy of adding bevacizumab to single-agent chemotherapy in platinum-refractory recurrent ovarian cancer: A meta-analysis
|
Ergün, Y.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 44 |
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage
|
Ramadan, W.S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 45 |
15P Enhancement Platform for immune Cells (EPiC): invIOs’s innovative cell-therapy platform for creating personalized cancer treatments
|
Kuttke, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 46 |
108P Establishing a multi-modal tissue preparation and imaging workflow to study heterogeneity in neuroblastoma tumors
|
Humhal, V.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 47 |
83P Evaluation of response-predictive biomarkers for lisavanbulin: A phase II study in patients with recurrent glioblastoma
|
Lopez, J.S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 48 |
88P Evaluation of trending drug targets and technologies in current drug development
|
Repetto, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 49 |
24P Fibroblast growth factor receptor (FGFR) as a target for epigenetic therapies: A case review for a new approach to target tumors with somatic mutations/amplifications of FGFR
|
Nezami, M.A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 50 |
7P Global ring study determining reproducibility & comparability of CLDN18 testing assays in gastric cancer
|
Jasani, B.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 51 |
78P High resolution in situ analysis reveals phenotypic and functional diversification within single pancreatic tumour ducts
|
Michiels, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 52 |
44P HPV16-specific CD4 and CD8 T-cell activation and functionality in patients receiving combination PDS0101 immunotherapy
|
Wood, L.V.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 53 |
77P Impact of germline HLA genotypes on clinical outcomes in patients (pts) with solid tumors treated with immunotherapy
|
Vieito Villar, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 54 |
89P Impact of metformin on glucocorticoid-induced changes in systemic metabolism in patients with brain metastases from solid malignancies
|
De Braud, F.G.M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 55 |
81P Implementing genomic profiling as standard-of-care for glioblastoma patients
|
Fougner, V.N.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 56 |
65P Influence of efflux and uptake transporters on the pharmacokinetics of the SYK inhibitors entospletinib and lanraplenib
|
Loos, N.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 57 |
54P Inhibition of ATM vs ATR in combination with radiotherapy affects cellular toxicity and expression of immune checkpoint molecules differently in HNSCC
|
Jost, T.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 58 |
56P Inhibition of HIF-2α-dependent transcription with small molecule inhibitors may provide therapeutic benefit beyond renal cell carcinoma
|
Gauthier, K.S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 59 |
68P Investigating CDK4/6 palbociclib resistance mechanisms in MCF7 breast cancer cell line
|
Beutier, H.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 60 |
64P Isothermal chemical KRAS denaturation assay for monitoring stability and inhibitors interactions
|
Mahran, R.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 61 |
106P Knockout of lncRNA-CCAT1 with the use of CRISPR-Cas9 system and G7 PAMAM dendrimers influences apoptosis and proliferations of NSCLC cells
|
Iwanski, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 62 |
50P KRAS mutation, the molecular landscape of lung adenocarcinoma in the Portuguese population
|
Trabulo, C.F.P.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 63 |
14P Lentivirally overexpressed c-Myc promoter binding protein (MBP-1) localizes in the cytoplasm of human cutaneous melanoma cell lines increasing cell proliferation and glycolysis rate
|
Hippner-Kunicka, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 64 |
38P Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy
|
Hu, Y.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 65 |
60P MAPKAP1/SIN1: A promising therapeutic target in resistant BRAF-mutated melanoma
|
Ezine, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 66 |
72P MDM alterations in patients with advanced or metastatic cancers
|
Lugowska, I.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 67 |
16P Melatonin modulates energy metabolism and kinases signaling in ovarian cancer cells
|
Chuffa, L.G.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 68 |
103P Microsomal triglyceride transfer protein as a prognostic and therapeutic marker for brain cancer
|
Kwon, R.J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 69 |
91P Molecular predictors of response to the therapy with mitotane in adrenocortical cancer
|
Porubayeva, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 70 |
67P Molecular testing and treatment of patients with advanced solid tumors harboring an NTRK gene fusion: Interim results of the REALTRK registry
|
Vannier, C.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 71 |
71P Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience
|
Crimini, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 72 |
26P 3MST: A potential workhorse in H2S signaling trimmed by microRNA-548 in breast cancer
|
Dawoud, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 73 |
20P Mutational signature-based identification of DNA repair deficient gastroesophageal adenocarcinomas for therapeutic targeting
|
Sahgal, P.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 74 |
58P Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low-expressing breast cancer cells and organoid mode
|
Arshad, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 75 |
17P New therapeutic target in triple-negative breast cancer for enhancing PARP inhibitor efficacy and stimulating the anti-tumour immune response
|
Rodriguez-Candela Mateos, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 76 |
33P Nomogram to predict survival of patients with unresectable melanoma receiving immune checkpoint inhibitors
|
Chatziioannou, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 77 |
4P Optimizing utilization of antibody-drug conjugates in NSCLC by identification of subsets using RNA sequencing
|
Lin, E.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 78 |
69P Osimertinib is selective against NSCLC cells and modulates the multidrug-resistant phenotype in patient-derived cell cultures and co-cultures of NSCLC cells and fibroblasts
|
Jovanović Stojanov, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 79 |
18P PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response
|
Zakharova, V.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 80 |
101P Prediction of radiation responses in patients with locally advanced rectal cancer with a patient-derived organoid-based radiosensitivity model
|
Phuwapraisirisan, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 81 |
76P Prediction of response to palliative chemotherapy by circulating tumor DNA (ctDNA) kinetics in metastatic pancreatic cancer
|
Kirchweger, P.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 82 |
43P Prognostic impact of the tumor immune microenvironment in adrenocortical cancer
|
Pachuashvili, N.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 83 |
99P Quantitative indicators of TREC and KREC excision rings in malignant neoplasms
|
Sultanbaev, A.V.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 84 |
84P Racial disparities in phase I lung cancer clinical trials
|
Singh, R.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 85 |
6P RC48-ADC for metastatic salivary duct carcinoma with HER2 expression: A single-center retrospective study
|
Cao, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 86 |
25P Relationship between aberrant methylation of CpG islands of microRNA gene promoters and changes in their expression in epithelial ovarian cancer
|
Pronina, I.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 87 |
63P Role of EGFR-targeted therapy in the treatment of advanced and metastatic cervical cancers
|
Krishna, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 88 |
100P RS-0139, a novel tumor-targeted delivery of docetaxel, with potent anti-tumor activity in a broad spectrum of tumor cell lines and xenograft models
|
Nomak, G.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 89 |
2P SOT102, a novel CLDN18.2-targeting antibody-drug conjugate for gastric and pancreatic cancer with a wide range of the tumor target expression
|
Spisek, R.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 90 |
85P Stereotactic radiotherapy improves disease control in oligoprogressive patients included in early clinical trials
|
Mavrikios, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 91 |
11P Successful transfer and prolonged persistence of engineered lymphocytes with T-cell receptor targeting NY-ESO-1
|
Arnon, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 92 |
23P Synthetic lethality by targeting RHEB in ARID1A-mutated luminal breast cancer
|
Ozturk, D.G.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 93 |
94P Targeted therapy in pediatric acute myeloid leukemia: An unmet need
|
Teja, B.R.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 94 |
75P Target identification by TIME phenotypes
|
Seitz, R.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 95 |
66P Targeting allosteric sites on PDK-1 and PLK-1 with bioactive compounds from Daucus carota as a potential therapy for triple-negative breast cancer
|
Raheem, K.Y.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 96 |
8P Targeting antiapoptotic Bcl-2 proteins with highly specific BH3 mimetics in solid tumors
|
Sobol, B.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 97 |
34P Targeting LSD1 rescues MHC-I antigen presentation and overcomes resistance to PD-L1 checkpoint blockade in small cell lung cancer
|
Nguyen, E.M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 98 |
61P The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma
|
Jung, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 99 |
96P The Hammersmith score optimises patient selection and predicts for overall survival in early-phase cancer trial participants independent of tumour burden
|
Korolewicz, J.A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 100 |
59P The influence of the ABCB1, ABCG2 and OATP1 transporters and the CYP3A enzyme on the bioavailability and tissue distribution of TPX-0131
|
Rijmers, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 101 |
36P Therapeutic vaccination with HPV-16 oncoproteins fused into a checkpoint modifier of early T cell activation protects against HPV-associated tumors in a preclinical model
|
Currie, S.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 102 |
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells
|
Hohenegger, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 103 |
105P Thoracic radiotherapy and tyrosine kinase inhibitors association: Results from a monoinstitutional experience
|
Nuccio, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 104 |
5P Tisotumab vedotin (TV) dose schedule optimization in non-cervical populations
|
Voellinger, J.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 105 |
51P Toxicity profile in early clinical trials with fibroblast growth factor receptor (FGFR) inhibitors (FGFRi): 10-years experience of a drug development unit
|
Rojas Laimito, K.I.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 106 |
49P Treatment management in RAS and BRAF mutations in patients with metastatic colorectal cancer
|
Özkan, M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 107 |
74P Tumor agnostic comparison of immunohistochemistry and next-generation sequencing in detecting ALK fusions and assessment of ALK tyrosine kinase inhibitor efficacy
|
Chen, M.F.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 108 |
19P Tumour-infiltrating neutrophil progenitors impair homologous DNA repair and promote sensitivity to PARP-inhibition
|
Calcinotto, A.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 109 |
13P Universal prospects of cryopreserved umbilical cord blood CD34+ progenitor cell-derived NK cells: Clinical and preclinical evaluation of non-engineered and genetically engineered candidates
|
Georgoudaki, A-M.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 110 |
86P Validation of the Gustave Roussy Immune (GRIm) score in patients treated with bispecific CD3 T cell engagers in phase I clinical trials
|
Herbel, N.
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 111 |
Table of Contents
|
|
|
|
8 |
1S2 |
p.
|
artikel
|
| 112 |
Title Page
|
|
|
|
8 |
1S2 |
p.
|
artikel
|
Tijdschrift beschrijving